Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Imprimis Pharma to...

    Imprimis Pharma to make cheaper alternative to Retrophin's Thiola

    Written by savita thakur thakur Published On 2016-02-11T12:42:42+05:30  |  Updated On 11 Feb 2016 12:42 PM IST
    Imprimis Pharma to make cheaper alternative to Retrophins Thiola
    Compounding pharmacy Imprimis Pharmaceuticals Inc said, it plans to make a cheaper alternative to Retrophin Inc's kidney stone drug, Thiola.

    Retrophin, under former Chief Executive Martin Shkreli, raised the price of the drug from $1.50 to $30 per tablet after buying the rights from Mission Pharmacal Co in 2014, Imprimis said.

    After Shkreli's departure, the price of Thiola still remains high, Imprimis said.

    The drug treats cystinuria, an inherited disease that causes stones made of the amino acid, cystine, in the kidneys, bladder or urethra.

    Imprimis said its compounded alternative may reduce the cost of the drug by more than 70 percent and will be available to patients in April.

    The company also makes a $1 copycat of Turing Pharmaceuticals' anti-infective drug, Daraprim, whose price was raised from $13.50 to $750 per pill by Shkreli's in a controversial move.

    Imprimis had said it sees an opportunity to build a market in countering massive drug price hikes.

    Unlike Thiola, Imprimis's formulation in itself is not FDA approved, and can only be used when prescribed by a doctor for a particular patient.

    Compounded therapies are not subjected to the same level of safety and efficacy evaluation and may not offer the same therapeutic outcome for patients, Retrophin said in a separate statement.
    Chief Executive Martin ShkreliImprimisImprimis PharmaImprimis Pharmaceuticalskidney stonekidney stone drugThiolaUSFDA
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok